Aclaris Therapeutics Inc (ACRS) Stake Lowered by Monashee Investment Management LLC

Monashee Investment Management LLC lessened its position in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 67.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 26,700 shares of the biotechnology company’s stock after selling 54,800 shares during the period. Monashee Investment Management LLC’s holdings in Aclaris Therapeutics were worth $658,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in ACRS. BlackRock Inc. lifted its stake in shares of Aclaris Therapeutics by 28.4% in the 4th quarter. BlackRock Inc. now owns 2,195,028 shares of the biotechnology company’s stock worth $54,129,000 after acquiring an additional 485,146 shares during the period. Alyeska Investment Group L.P. lifted its stake in shares of Aclaris Therapeutics by 85.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 467,884 shares of the biotechnology company’s stock worth $12,076,000 after acquiring an additional 215,201 shares during the period. Citadel Advisors LLC lifted its stake in shares of Aclaris Therapeutics by 620.6% in the 3rd quarter. Citadel Advisors LLC now owns 242,016 shares of the biotechnology company’s stock worth $6,247,000 after acquiring an additional 208,429 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Aclaris Therapeutics by 147.6% in the 4th quarter. Bank of New York Mellon Corp now owns 272,404 shares of the biotechnology company’s stock worth $6,718,000 after acquiring an additional 162,389 shares during the period. Finally, State Street Corp lifted its stake in shares of Aclaris Therapeutics by 67.1% in the 2nd quarter. State Street Corp now owns 330,755 shares of the biotechnology company’s stock worth $8,971,000 after acquiring an additional 132,866 shares during the period. Institutional investors own 87.06% of the company’s stock.

Shares of Aclaris Therapeutics Inc (ACRS) opened at $20.01 on Thursday. Aclaris Therapeutics Inc has a 52 week low of $18.46 and a 52 week high of $33.25. The company has a market cap of $613.92, a PE ratio of -9.26 and a beta of 1.26.

Several analysts have recently commented on ACRS shares. Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Monday, January 8th. Guggenheim started coverage on shares of Aclaris Therapeutics in a research note on Thursday, February 8th. They issued a “buy” rating and a $53.00 target price for the company. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Finally, BidaskClub upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Aclaris Therapeutics currently has an average rating of “Hold” and an average target price of $41.80.

WARNING: “Aclaris Therapeutics Inc (ACRS) Stake Lowered by Monashee Investment Management LLC” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/22/aclaris-therapeutics-inc-acrs-stake-lowered-by-monashee-investment-management-llc.html.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics Inc (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply